GSK-444563/005 (rota-005)

Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Biologicals’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus
Rotavirus Vaccine
444563/005 (rota-005)
Infections, Rotavirus
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided.
June 2015